Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 16, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KALA BIO, Inc.
Report date June 16, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2032-06-15 | Direct | 40,000 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 40,000 · Balance 40,000 F1: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2022 Filed Jun 17, 2022 20:45 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-22-006750 · form4-06172022_040606.xml · derivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:30 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003122 · form4-06212021_050617.xml · nonDerivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021. F2 · balance_after: Includes 20,000 unvested RSUs. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:52 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078319 · a4.xml · nonDerivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the earlier of (i) June 25, 2021 or (ii) the date of the first annual meeting following June 25, 2020. F2 · balance_after: Includes 20,000 unvested RSUs Read SEC document |
| March 11, 2020 Filed Jun 30, 2020 01:51 UTC | KALA BIO, Inc. KALA · Entity 7964 | OtherCommon Stock | 1,287 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078317 · a4.xml · nonDerivative · entry 3 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,361 F1 · kind: Pro rata distribution for no consideration to the reporting person from Lux Ventures II, L.P., of which the reporting person is a non-managing member. F2 · balance_after: Prior reports filed on July 19, 2017 and July 26, 2017 by the reporting person overstated the number of shares beneficially owned by Mr. Paull by 1,204,937 shares by incorrectly reporting that Mr. Paull had beneficial ownership of 1,156,441 shares held directly by Lux Ventures II, L.P. and 48,496 shares held by Lux Ventures II Sidecar, L.P. F3 · ownership.nature: These shares are owned directly by The paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:02 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001104659-19-034523 · a4.xml · derivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:46 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001179110-18-008523 · edgar.xml · derivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Underlying: Common Stock · 12,960 shares Expires 2028-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 11, 2018 Filed Jun 30, 2020 01:51 UTC | KALA BIO, Inc. KALA · Entity 7964 | OtherCommon Stock | 477 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078317 · a4.xml · nonDerivative · entry 2 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,074 F1 · kind: Pro rata distribution for no consideration to the reporting person from Lux Ventures II, L.P., of which the reporting person is a non-managing member. F2 · balance_after: Prior reports filed on July 19, 2017 and July 26, 2017 by the reporting person overstated the number of shares beneficially owned by Mr. Paull by 1,204,937 shares by incorrectly reporting that Mr. Paull had beneficial ownership of 1,156,441 shares held directly by Lux Ventures II, L.P. and 48,496 shares held by Lux Ventures II Sidecar, L.P. F3 · ownership.nature: These shares are owned directly by The paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust. Read SEC document |
| May 18, 2018 Filed Jun 30, 2020 01:51 UTC | KALA BIO, Inc. KALA · Entity 7964 | OtherCommon Stock | 597 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078317 · a4.xml · nonDerivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 597 F1 · kind: Pro rata distribution for no consideration to the reporting person from Lux Ventures II, L.P., of which the reporting person is a non-managing member. F2 · balance_after: Prior reports filed on July 19, 2017 and July 26, 2017 by the reporting person overstated the number of shares beneficially owned by Mr. Paull by 1,204,937 shares by incorrectly reporting that Mr. Paull had beneficial ownership of 1,156,441 shares held directly by Lux Ventures II, L.P. and 48,496 shares held by Lux Ventures II Sidecar, L.P. F3 · ownership.nature: These shares are owned directly by The paull Revocable Trust U/A/D 04/06/2012 (the "Trust"), and indirectly by Mr. Paull as co-trustee of the Trust. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionCommon Stock Warrant (right to buy) · Derivative | 16,152 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 7 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 16,152 Underlying: Common Stock · 16,152 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · derivative.expiration_date: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F9 · ownership.nature: Includes Common Stock Warrants to purchase (a) 15,502 shares of Series Common Stock that are held by Lux Ventures II, L.P. and (b) 650 shares of Common Stock that are held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionSeries B Preferred Stock Warrant (right to buy) · Derivative | 84,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 6 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Series B Preferred Stock · 84,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · shares: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · derivative.exercise_date: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · derivative.expiration_date: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · derivative.underlying_shares: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F7 · balance_after: The Series B Preferred Stock Warrants were exercisable for such shares of Preferred Stock at an exercise price of $1.44 per share. Upon the closing of the Issuer's initial public offering, the Warrants automatically became exercisable for 16,152 shares of Common Stock at an exercise price of $7.50 per share. The Warrants are exercisable at any time at the holder's election. F8 · ownership.nature: Includes Series B Convertible Preferred Stock Warrants to purchase (a) 80,744 shares of Series B Convertible Preferred Stock that are held by Lux Ventures II, L.P. and (b) 3,386 shares of Series B Convertible Preferred Stock that are held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionSeries C Preferred Stock · Derivative | 31,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 5 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 6,046 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F6 · ownership.nature: Includes (a) 30,226 shares of Series C Convertible Preferred Stock that were held by Lux Ventures II, L.P. and (b) 1,268 shares of Series C Convertible Preferred Stock that were held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionSeries B Preferred Stock · Derivative | 900,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 4 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 172,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F5 · ownership.nature: Includes (a) 863,917 shares of Series B Convertible Preferred Stock that were held by Lux Ventures II, L.P. and (b) 36,229 shares of Series B Convertible Preferred Stock that were held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionSeries A Preferred Stock · Derivative | 1,666,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 3 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 320,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.nature: Includes (a) 1,599,586 shares of Series A Convertible Preferred Stock that were held by Lux Ventures II, L.P. and (b) 67,080 shares of Series A Convertible Preferred Stock that were held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionSeries Seed Preferred Stock · Derivative | 3,677,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · derivative · entry 2 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 706,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: Includes (a) 3,529,364 shares of Seed Convertible Preferred Stock that were held by Lux Ventures II, L.P and (b) 148,009 shares of Seed Convertible Preferred Stock that were held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 25, 2017 Filed Jul 26, 2017 20:31 UTC | KALA BIO, Inc. KALA · Entity 7964 | ConversionCommon Stock | 1,204,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-010705 · edgar.xml · nonDerivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 1,204,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: Includes (a) 1,156,441 shares of Common Stock that are held by Lux Ventures II, L.P. and (b) 48,496 shares of Common Stock that are held by Lux Ventures II Sidecar, L.P. The Reporting Person is a venture partner at Lux Capital Management, and disclaims beneficial ownership of the shares held by each of Lux Ventures II, L.P. and Lux Ventures II Sidecar, L.P., except to the extent of his pecuniary interest therein. Read SEC document |
| July 19, 2017 Filed Jul 21, 2017 20:20 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001179110-17-010594 · edgar.xml · derivative · entry 1 Paull Robert Bradley · CIK 0001711254 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Underlying: Common Stock · 12,960 shares Expires 2027-07-18 F1 · derivative.exercise_date: This option was granted, effective on July 19, 2017 and vests over one year, with 8.33% of the shares underlying the option vesting on August 19, 2017, and an addition 8.33% of the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.